INTRODUCTION
Acute kidney injury (AKI) is a common syndrome reported in 5% of the hospitalized and more than 30% of the critically ill patients [
1]. Despite advances in medical care, AKI is one of the most common and serious complications in hospitalized patients, and is associated with high rates of adverse outcomes during hospitalization and after discharge [
2,
3]. Chronic kidney disease (CKD) is another major concern associated with high mortality and morbidity [
4]. Although AKI and CKD were considered to be distinct pathologies, recent epidemiological and mechanistic studies suggest that they are closely interconnected as AKI frequently leads to CKD, regardless of the cause of acute injury [
5]. Thus, a better understanding of the progression from AKI-to-CKD is warranted to develop suitable interventions.
AKI-to-CKD progression is a complex process that is poorly understood [
6]. Recent experimental studies have suggested an interplay between endothelial dysfunction, interstitial inflammation, fibrosis, and tubular epithelial injury underlying AKI-to-CKD progression [
7]. It has been proposed that injured tubular epithelial cells (TECs) play a central role in AKI-to-CKD progression [
7–
9], and drive inflammation by producing pro-inflammatory cytokines and chemokines [
10]. In addition, TECs contribute to renal fibrosis via epithelial-mesenchymal transition (EMT), a process in which epithelial cells lose their polarity and adhesion properties, and gain migratory and invasive properties to become mesenchymal cells [
7–
9,
11]. However, the contribution of EMT to kidney fibrosis remains controversial, as studies using genetic cell lineage tracing could not find evidence of direct contribution of epithelial cells to the myofibroblast population [
8]. Thus, in this manuscript, change of TEC upon kidney injury was expressed as tubular dedifferentiation, which refers to EMT-like morphological changes leading to reduced expression of epithelial markers and increased expression of mesenchymal markers. Although the extent to which EMT contributes to kidney fibrosis is yet to be fully elucidated, tubular dedifferentiation prompts one to appreciate the role of TECs in kidney fibrosis [
11].
Akt/protein kinase B (PKB) is a serine/threonine kinase, activated by phosphatidylinositide 3′-OH kinase (PI3K); it is a key regulator of cell proliferation, migration, apoptosis, angiogenesis, and metabolism [
12,
13]. Mammals express three Akt isoforms, Akt1, Akt2, and Akt3, that differ in their functions. While Akt1 is ubiquitously expressed, Akt2 expression is high in insulin-responsive tissues such as adipose tissue, liver, and skeletal muscle, and Akt3 is highly expressed in the brain [
13]. In the kidneys, Akt is involved in the proliferation and activation of interstitial fibroblasts, glomerular mesangial cells, and TECs during the development of renal fibrosis [
12]. Evidence also indicates that the Akt signaling pathway plays a role in tubular dedifferentiation [
11,
12].
The exact isoform(s) of Akt associated with tubulointerstitial fibrosis and tubular dedifferentiation during AKI-to-CKD progression remains unknown. In the present study, we established a unilateral ischemia-reperfusion injury (UIRI) without contralateral nephrectomy, a validated model of AKI-to-CKD progression with extensive tubulointerstitial fibrosis [
14], and investigated the role of Akt isoforms in tubulointerstitial fibrosis and tubular dedifferentiation during AKI-to-CKD progression.
DISCUSSION
In this study, we illustrated the critical role of Akt1 in renal fibrosis and tubular dedifferentiation during AKI-to-CKD progression. We found that Akt1, not Akt2 or Akt3, was activated during AKI-to-CKD progression, and that Akt1 deletion was associated with attenuated tubulointerstitial fibrosis and tubular dedifferentiation. The attenuation of renal fibrosis and tubular dedifferentiation caused by Akt1 deletion was independent of the TGF-β1/Smad pathway, and related to the GSK-3β, Snail, and β-catenin pathways.
The UIRI model without contralateral nephrectomy that was established in the present study is a robust system to study AKI-to-CKD progression [
14,
16,
18]. Ischemia-reperfusion injury (IRI) is a pathological process that aggravates into acute tubulointerstitial injury. Aside from nephrotoxic agents, ischemia is also known to be associated with human AKI. IRI is followed by a repair process, which attempts to restore the normal morphology and function of the kidney; however, in the case of severe injury, it may lead to permanent damage and progressive fibrosis [
16]. Thus, it is clinically relevant to analyze IRI for investigating AKI-to-CKD progression. Most experimental studies on renal fibrosis and CKD are performed in a unilateral ureter obstruction model (UUO), which is undoubtedly valuable for investigating the mechanism of AKI-to-CKD transition; however, this model correlates with a rare form of human renal disease [
18]. In the UIRI without contralateral nephrectomy model, the contralateral kidney is left intact; this improves the survival, and may even allow the establishment of severe injury [
18]. Short-term duration of ischemia (20 minutes) induces mild renal tubulointerstitial injury, and this effect is completely reversed during the acute phase of kidney injury. However, long duration of ischemia (30 or 45 minutes) causes severe tubular damage, apoptosis, and inflammatory infiltration during early disease stages, eventually leading to permanent chronic kidney fibrosis during the later stages (4 weeks after UIRI) [
16]. In another study, the injured kidney developed inflammatory cell infiltration and interstitial fibrosis 6 weeks after UIRI (30 minutes ischemia), consistent with a CKD phenotype [
18]. Based on the results of these studies, we established a murine model of AKI-to-CKD progression by harvesting injured kidneys 6 weeks after UIRI without contralateral nephrectomy at an ischemia time of 30 minutes.
Previous studies have demonstrated the role of Akt in tubulointerstitial fibrosis and tubular dedifferentiation. In a murine model of UUO, PI3K/Akt activity is increased in ligated kidneys compared to that in non-ligated kidneys [
19]. Akt activation is associated with cell proliferation and extracellular matrix deposition in ligated kidneys [
19]. Treatment with PI3K inhibitor, Ly294002, was shown to suppress UUO-induced tubulointerstitial fibrosis, as evidenced by decreased expression of fibroblast markers and extracellular matrix deposition in the interstitium [
20]. Moreover, Ly294002 reduced the number of proliferating cells in the interstitium and tubules [
20]. The role of Akt2 was investigated in renal fibrosis following UUO, and the knockdown of Akt2 was shown to suppress UUO-induced tubulointerstitial fibrosis; indicative of the important function of Akt2 in renal fibrosis following UUO [
17].
Akt2 deletion also suppressed UUO-induced tubular dedifferentiation, increased expression of GSK-3β, and decreased Snail and β-catenin levels, suggesting that Akt2 may play an important role in tubular dedifferentiation following UUO [
17]. With respect to IRI-induced AKI, Akt phosphorylation was shown to be increased after IRI in mouse kidney, but was reduced upon treatment with a PI3K inhibitor, wortmannin [
21]. The proliferation of renal tubular cells increased after IRI in mouse kidney, and this effect was inhibited by wortmannin [
21]. These findings suggest that PI3K/Akt signaling is associated with the regulation of renal repair after IRI. Taken together, Akt plays an important role, not only in IRI-induced AKI but also in tubulointerstitial fibrosis. Therefore, we hypothesized that Akt signaling is involved in AKI-to-CKD progression and investigated the role of Akt isoforms in a murine model of AKI-to-CKD progression.
Here, we found that the phosphorylation and activation of Akt1 increased in WT UIRI mice compared to that in WT sham mice, suggesting that, in this model, Akt1 may play an important role in tubulointerstitial fibrosis. However, there is a possibility of compensatory activation of other isoforms (Akt2 or Akt3) that may contribute to tubulointerstitial fibrosis. As Akt3 protein expression is absent in the kidney [
17], we investigated the levels of p-Akt2 in WT UIRI and
Akt1−/− UIRI mice and found no difference in the level of p-Akt2 between the two groups. Thus, attenuation of tubulointerstitial fibrosis in
Akt1−/− UIRI mice was primarily associated with
Akt1 deletion, not with the compensatory activation of Akt2.
During AKI-to-CKD transition, injured TECs may directly contribute to renal fibrosis via EMT [
8]. EMT is a biological process that allows a polarized epithelial cell—which normally interacts with the basement membrane through its basal surface—to undergo multiple biochemical changes, enabling it to assume a mesenchymal phenotype characterized by enhanced migratory capacity, invasiveness, elevated resistance to apoptosis, and increased production of extracellular matrix [
22]. Thus, EMT is associated with the loss of epithelial markers (E-cadherin, zonular occludens-1, and cytokeratin) and the gain of mesenchymal features (vimentin, α-SMA, fibroblast-specific protein-1, and fibronectin) [
8]. Although the present study did not show direct evidence of tubular EMT, it demonstrated an increase in tubular dedifferentiation in WT UIRI mice during AKI-to-CKD progression, consistent with a decrease in the expression of E-cadherin and increase in the levels of vimentin/α-SMA. The genetic deletion of
Akt1 resulted in the attenuation of UIRI-induced tubular dedifferentiation, suggestive of the involvement of Akt1 in tubular dedifferentiation during AKI-to-CKD progression.
TGF-β1 signaling plays a crucial role in mediating renal fibrosis [
11]. TGF-β1 exerts its pathological activities via Smad-dependent and Smad-independent signaling pathways [
11,
23]. In the Smad-dependent pathway, the binding of TGF-β1 to its receptor leads to the phosphorylation of Smad2/3. The p-Smad2/3 complex then translocates into the nucleus to regulate the transcription of fibrotic markers [
11,
23]. The Smad-independent TGF-β1 signaling pathway involved in renal fibrosis includes RhoA, p38-mitogen-activated protein kinase, and PI3K/Akt [
23]. In the present study, we found that the levels of TGF-β1 and p-Smad2/3 increased in both WT UIRI and
Akt1−/− UIRI mice compared to those in WT sham mice, suggesting upregulation of TGF-β1/Smad signaling during AKI-to-CKD progression. However, Western blot analysis showed no difference in the expression of TGF-β1 and p-Smad2/3 between WT UIRI and
Akt1−/− UIRI mice. Immunohistochemistry and real-time PCR further demonstrated a lack difference in TGF-β1 expression between the two groups. Thus, the attenuation of tubular dedifferentiation and renal fibrosis by the genetic deletion of
Akt1 may not be associated with TGF-β1/Smad signaling. Indeed, the PI3K/Akt signaling pathway functions independently to modulate EMT in cancer cells, and has attracted attention as a potential target for the prevention and treatment of metastatic tumors [
24]. Taken together, we suggest that Akt1 plays an independent role in tubular dedifferentiation and renal fibrosis, regardless of TGF-β1/Smad signaling, during AKI-to-CKD progression. Further studies are needed to confirm this hypothesis.
The present study provides an insight into the mechanism underlying Akt1-mediated tubular dedifferentiation during AKI-to-CKD progression. GSK-3β is a downstream target of PI3K/Akt signaling, which is necessary for maintaining the epithelial architecture [
25]. Activation of PI3K/Akt results in the induction of the phosphorylation and functional inactivation of GSK-3β [
26,
27]. GSK-3β inhibition is implicated in EMT in various epithelial cells, including breast and skin cells [
27]. In rat kidney epithelial cells, inhibition of PI3K/Akt activity attenuates TGF-β1-mediated tubular dedifferentiation by decreasing GSK-3β phosphorylation [
26]. In the present study, GSK-3β phosphorylation increased in WT UIRI mice during AKI-to-CKD progression, but was decreased in
Akt1−/− UIRI mice. Our findings suggest that the decrease in GSK-3β phosphorylation following genetic deletion of
Akt1 may result in the attenuation of tubular dedifferentiation during AKI-to-CKD progression. Snail is a transcription factor that binds to the promoter region of E-cadherin and suppresses
E-cadherin mRNA production [
27]. In addition to Snail, nuclear accumulation of β-catenin is a typical feature of tubular dedifferentiation [
26]. As the phosphorylation and functional inactivation of GSK-3β results in the stabilization of cytoplasmic β-catenin and Snail [
26], we measured the expression of Snail and β-catenin in our murine model of AKI-to-CKD progression and found it to be markedly increased in WT UIRI mice, but attenuated in
Akt1−/− UIRI mice. Taken together, our study indicates that the attenuation of tubular dedifferentiation by genetic deletion of
Akt1 is associated with decreased expression of p-GSK-3β, Snail, and β-catenin. Thus, these findings highlight the role of the Akt1/GSK-3β/(Snail and β-catenin) pathway in tubular dedifferentiation during AKI-to-CKD progression.
Akt isoforms have different functions and may induce different phenotypes in a cell- and disease-dependent manner [
28,
29]. For instance, Akt2 is essential for maintaining podocyte viability and function in a murine model of 75% nephron reduction [
29]. Akt2 is also thought to be involved in renal fibrosis in a murine model of unilateral ureteral obstruction [
17]. The present study demonstrates the involvement of Akt1 in tubular dedifferentiation and renal fibrosis in a murine model of UIRI without contralateral nephrectomy. It is unclear why the role of Akt isoforms varies depending on the renal fibrosis model. We believe that further studies are needed regarding renal fibrosis models other than UUO, 75% nephron reduction, and IRI, to elucidate the roles of Akt isoforms in the renal fibrosis.
The conclusions of the present study are summarized in
Fig. 6. We demonstrated that the genetic deletion of
Akt1 results in the attenuation of tubulointerstitial fibrosis and tubular dedifferentiation during AKI-to-CKD progression in a murine model of UIRI without contralateral nephrectomy. This effect was associated with a decrease in the levels of p-GSK-3β, Snail, and β-catenin, independent of the TGF-β1/Smad pathway. Thus, Akt1 could serve as a potential novel therapeutic target for inhibiting AKI-to-CKD progression. However, further studies are needed to determine, to what extent the tubular dedifferentiation by Akt1 contributes to renal fibrosis during AKI-to-CKD progression. Additional studies are also needed to determine if Akt1 plays roles other than tubular dedifferentiation in renal fibrosis.